Work

Daratumumab Plus Lenalidomide and Dexamethasone (DRd) Compared to Daratumumab Plus Pomalidomide and Dexamethasone (DPd) in Relapsed Lenalidomide-Exposed or Refractory Multiple Myeloma (MM) Patients: The Mayo Clinic Experience

Year: 2020

Type: article

Study design: Observational Study

Source: Blood

DOI: 10.1182/blood-2020-139929

Authors: Muhamad Alhaj Moustafa, Ricardo Parrondo, Mays F Abdulazeez, Vivek Roy, Taimur Sher, Victoria R. Alegria, Rahma M Warsame, Jeremy Larsen, Wilson I Gonsalves, Taxiarchis Kourelis, Prashant Kapoor, Rafael Fonseca, Francis K. Buadi, David Dingli, Suzanne R. Hayman, Craig B. Reeder, Arshi Agrawal, Asher A. Chanan-Khan, Sikander Ailawadhi

Institutions: Mayo Clinic, Mayo Clinic in Florida, Mayo Clinic Hospital, Mayo Clinic in Arizona

Language: English

Topic: Multiple Myeloma Research and Treatments

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W3097903462

FWCI:

Cites:

Cited by:

Related to: 10